Display options
Cite
Chen D, Cheng J, Yang K, et al. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013;6:1507-14doi: 10.2147/OTT.S53098.
Chen, D., Cheng, J., Yang, K., Ma, Y., & Yang, F. (2013). Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets and therapy, 61507-14. https://doi.org/10.2147/OTT.S53098
Chen, Dan, et al. "Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma." OncoTargets and therapy vol. 6 (2013): 1507-14. doi: https://doi.org/10.2147/OTT.S53098
Chen D, Cheng J, Yang K, Ma Y, Yang F. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013. PMID: 24187501; PMCID: PMC3810446.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013.

Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

OncoTargets and therapy

Dan Chen, Jue Cheng, Kai Yang, Yue Ma, Fang Yang

Affiliations

  1. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.

PMID: 24187501 PMCID: PMC3810446 DOI: 10.2147/OTT.S53098

Abstract

BACKGROUND: Chronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil (5-Fu) can significantly improve efficacy and reduce the incidence of adverse events in patients with metastatic colorectal cancer, as compared with conventional chemotherapy. However, the results may be different in different tumors. Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is very difficult to treat, with an extremely unfavorable prognosis. So far, no report is available on chronomodulated chemotherapy for HNSCC.

METHODS: Retrospective analyses were made on 49 patients with local recurrent and/or metastatic HNSCC who underwent palliative treatments with paclitaxel, carboplatin, and 5-Fu. The patients were divided into a chronomodulated chemotherapy group (28 patients) and a conventional chemotherapy group (21 patients) according to their administration times. The two groups were compared for tumor objective response rate, overall survival (OS), progression-free survival (PFS), and the incidence of adverse events.

RESULTS: The tumor objective response rate and patients' OS were significantly higher and longer in the chronomodulated chemotherapy group than in the conventional chemotherapy group (71.43% versus 42.86%, respectively, P<0.05; and median OS 15.3 months versus 10.6 months, respectively, P<0.05). However, PFS was similar statistically (median PFS 11.6 months versus 7.2 months, P>0.05). The global incidence of adverse events in the chronomodulated chemotherapy group was significantly lower than that in the conventional chemotherapy group (46.43% versus 76.19%, P<0.05), with significantly lower incidence of grade 3-4 adverse events (7.14% versus 33.33%, P<0.05).

CONCLUSION: Chronomodulated chemotherapy with paclitaxel, carboplatin, and 5-Fu may be a new and effective therapy for patients with recurrent and/or metastatic HNSCC as compared with conventional chemotherapy.

Keywords: 5-fluorouracil; carboplatin; chronomodulated chemotherapy; chronotherapy; head and neck cancer; paclitaxel; palliative chemotherapy

References

  1. J Int Med Res. 2011;39(6):2061-6 - PubMed
  2. J Clin Pharm Ther. 2012 Jun;37(3):342-7 - PubMed
  3. Br J Cancer. 2010 Oct 12;103(8):1173-81 - PubMed
  4. N Engl J Med. 2007 Oct 25;357(17):1695-704 - PubMed
  5. Cancer Causes Control. 2006 May;17(4):611-21 - PubMed
  6. Head Neck. 2013 Mar;35(3):443-53 - PubMed
  7. Ann Oncol. 1994 Feb;5(2):113-7 - PubMed
  8. Int J Cancer. 1997 Jan 17;70(2):241-7 - PubMed
  9. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35 - PubMed
  10. Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24 - PubMed
  11. J Clin Epidemiol. 2004 Apr;57(4):358-65 - PubMed
  12. Cancer. 2008 Jun 15;112(12):2635-45 - PubMed
  13. Am J Clin Oncol. 2000 Apr;23(2):128-31 - PubMed
  14. Ann Oncol. 2010 Oct;21 Suppl 7:vii252-61 - PubMed
  15. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  16. Cancer Chemother Pharmacol. 2005 Mar;55(3):271-6 - PubMed
  17. J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 - PubMed
  18. Ann Oncol. 2004 Apr;15(4):638-45 - PubMed
  19. Int J Cancer. 2006 Apr 1;118(7):1623-7 - PubMed
  20. Annu Rev Pharmacol Toxicol. 2010;50:377-421 - PubMed
  21. Cancer Res. 1998 Sep 1;58(17):3896-904 - PubMed
  22. Eur J Pharm Sci. 2009 Jan 31;36(1):20-38 - PubMed
  23. Ann Oncol. 1997 May;8(5):445-9 - PubMed
  24. Cancer Res. 2001 Mar 1;61(5):1996-2001 - PubMed
  25. J Infus Chemother. 1995;5(3 Suppl 1):148-52 - PubMed
  26. Ann Oncol. 2005;16 Suppl 2:ii258-64 - PubMed

Publication Types